Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Inyta

- PMLiVE

The journey to market access 5.0

Few in pharma are unaware of the importance of delivering demonstrable value in collaboration with payers. But are we serious about patient outcomes?

- PMLiVE

GSK persuades NICE to reconsider negative Benlysta decision

Decision on lupus drug referred to expert committee following appeal

- PMLiVE

Market access webinar series begins with UK healthcare changes

Experts convene for first Sudler & Hennessey and Kantar Health online event

- PMLiVE

Pfizer’s Andrew Thomas takes up UK comms agency role

Joins London-based Red Door Communications as head of international

Pfizer gets US approval for leukaemia drug Bosulif

FDA grants the tyrosine kinase inhibitor a licence to treat chronic myelogenous leukaemia

- PMLiVE

Pfizer’s Inlyta gets EU approval for advanced kidney cancer

Available as second-line therapy after treatment with pharma firm's own Sutent

- PMLiVE

Astellas Pharma Europe appoint new senior director, market access

Dr Susan Wood was previously senior brand director of the company’s pain management franchise 

- PMLiVE

Pfizer dealt another blow as Torisel fails kidney cancer trial

Results are another setback in company's bid to extend the indications for its mTOR inhibitor

- PMLiVE

End of the line for intravenous bapineuzumab in Alzheimer’s

Negative trial results for Pfizer and Johnson & Johnson to concede defeat

- PMLiVE

Pfizer sells Kent R&D centre to property consortium

Discovery Park Ltd takes over site 18 months after US pharma firm announced plans to exit it

- PMLiVE

Interview: Deepak Khanna, ABPI

Collaboration, communication and an appropriate drug pricing scheme are key says ABPI president

- PMLiVE

Pillars of success in market access

The key to true market access success begins with corporate ownership…

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links